We also examined the effect of treatment on the kidney, because of the suggestion in the literature that there is a possibility that there could be an increase in kidney damage in NASH with inhibition of gal-3 [11], [27]. Here, LGALS3 is linked to metabolic dysfunction-associated steatohepatitis.